Loading...
XNYS
DVA
Market cap14bUSD
Jul 09, Last price  
229.48USD
1D
-0.54%
1Q
52.94%
Jan 2017
257.45%
Name

DaVita Inc

Chart & Performance

D1W1MN
XNYS:DVA chart
P/E
19.72
P/S
1.08
EPS
11.64
Div Yield, %
Shrs. gr., 5y
-6.40%
Rev. gr., 5y
3.39%
Revenues
13.64b
+6.46%
4,880,662,0005,264,151,0005,660,173,0006,108,800,0006,447,391,0006,791,980,0008,186,280,00011,764,050,00012,795,106,00013,781,837,00014,745,105,00010,876,634,00011,404,851,00011,388,479,00011,550,604,00011,618,797,00011,609,894,00012,140,147,00012,815,550,00013,643,069,000
Net income
747m
-20.24%
289,691,000381,778,000374,160,000422,684,000405,683,000478,001,000536,017,000633,446,000723,114,000269,732,000879,874,000663,618,000159,394,000810,981,000773,642,000978,450,000560,400,000691,535,000936,342,000746,803,000
CFO
1.89b
-6.70%
519,571,000533,036,000555,931,000666,710,000839,683,0001,180,046,0001,100,848,0001,773,341,0001,459,407,0001,557,200,0001,963,444,0001,907,449,0001,771,640,0002,072,355,0001,979,028,0001,930,876,0001,564,570,0002,059,031,0002,022,038,0001,886,500,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
IPO date
Oct 31, 1995
Employees
70,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT